Aurobindo Pharma Strong Growth in Q3FY26 Driven by Europe and Stable US Performance
Aurobindo Pharma reported robust financial results for the third quarter of FY26 (Q3FY26), achieving a consolidated revenue of ₹8,646 Cr,…
Rallis India Limited Appointment of Mr. Ashok Sharma as Additional Director
Rallis India Limited announced the appointment of Mr. Ashok Sharma (DIN: 02766679) as an Additional Director, effective February 10, 2026. He…
YES BANK Redemption of INR 76 Crores from Security Receipts Portfolio Post NPA Sale
YES BANK announced the receipt of a significant redemption amount of INR 76 Crores. This redemption stems from a single trust within the…
HUDCO Approves Enhancement of Annual Borrowing to ₹80,000 Crore and Intimates Issuance of Perpetual Bonds
The Board of Directors has approved an enhancement of the annual borrowing program for FY 2025-26 from ₹65,000 crore to ₹80,000 crore. This…
Embassy Developments Reports ~240% QoQ Growth in Pre-sales in Q3 FY26; Key RERA Approvals Strengthen FY26 Outlook
Embassy Developments Limited announced exceptional results for Q3 FY26 (ending December 31, 2025), highlighted by a massive ~240%…
Supriya Lifescience Ltd. Board Approves Q3 FY2025 Financial Results and Key Director Appointments
Supriya Lifescience Ltd. announced the outcome of its Board Meeting held on February 09, 2026. The Board approved the Unaudited Financial…
Wipro Limited Completion of Equity Subscription in AMPIN Energy C&I One Private Limited
Wipro Limited has formally announced the completion of its definitive agreement to subscribe to the equity share capital of AMPIN Energy…
LatentView Analytics Q3 FY’26 Earnings Call Transcript Highlights Strong Sequential Growth and AI Strategy Deep Dive
LatentView Analytics reported its 12th consecutive quarter of sequential growth for Q3 FY’26, with dollar revenue increasing by 5.7% (8%…
Adani Enterprises Limited Record Date Fixed for Second and Final Call on Partly Paid Rights Shares
Adani Enterprises Limited has announced the Record Date for the Second and Final Call payment pertaining to its partly paid-up equity rights…
Privi Speciality Chemicals Limited Board Approves Q3 FY2025-26 Results and ₹50 Crore Equity Infusion in Subsidiary
Privi Speciality Chemicals Limited announced the outcome of its Board meeting held on February 09, 2026. The board approved the Unaudited…